accentus
       Site Map
 
Utilisation of plasma spraying techniques to apply a full range of bioactive coatings to implants manufactured by several global orthopaedic manufacturers.
Technologies
Licensing
   

Orthopaedics

 

Orthopaedic coatings

The coating of orthopaedic implants, such as total joint replacement prostheses, is undertaken with the aim of either increasing the wear resistance of the implant materials or to provide an implant surface which increases the biocompatibility of the prosthesis with the surrounding host bone. This increase in biocompatibility leads to the formation of new bone around the implant resulting in better fixation and improved long term performance of the replacement joint.

Accentus utilises plasma spraying techniques to apply a full range of bioactive coatings to implants manufactured by several global orthopaedic manufacturers. These coatings include :- Titanium, TiVAl alloy,CoCrMo alloy and Hydroxyapatite. Our coating facilility is approved to ISO 9000 - 2000 standards and our coatings have received all of the regulatory approvals needed for free sale in Europe and North America.

A successful example of our coating processes is the plasma sprayed deposition of bio-active Hydroxyapatite (HA) onto the surface of joint replacements. Such coatings give the benefits of:

  • Greater acceleration of healing process
  • Reduced risk of post-operative infection
  • Active encouragement of bone growth
  • Better body acceptance, lower rejection
  • Improved long term prosthesis fixation

Extensive mechanical and histological analyses carried out in Accentus's laboratories have demonstrated the efficacy of our coatings and many clinical papers published by our customers have proven the performance of our coatings in the clinical environment.

The photograph above shows the interface of bone and metal implant (M) with "bi" titanium and hydroxyapatite (HA) coating. Actively forming bone (B) with osteoid seams is visible both at and near the bone - implant interface. The bone was stained by Toluidine blue and viewed with a x20 objective, 3 months after insertion of implant.

Top of page >

 
 
Related links
 
© copyright Accentus plc 2009